AlphaStocks
1.4
Avoid

CORCEPT THERAPEUTICS INC (CORT)

Health Care / Pharmaceuticals

S&P SmallCap 600

$41.99

Scores poorly across most models. Proceed with caution.

Avoid

Score based on 4 of 5 models — moderate confidence

#1112out of 1127 in Health Care

Is CORCEPT THERAPEUTICS INC a Good Investment in 2026?

CORCEPT THERAPEUTICS INC (CORT) scores 1.4 out of 10 on AlphaStocks' composite model, earning a Avoid rating. The Piotroski model is the most favorable, rating CORCEPT THERAPEUTICS INC as Neutral. However, the Graham model rates it Caution — Significantly above fair value. CORCEPT THERAPEUTICS INC currently trades above its estimated fair value of $23, suggesting limited upside at current prices. CORCEPT THERAPEUTICS INC ranks #1112 out of 1127 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E50.5ROE10.5Market Cap5B

Estimated Fair Value

$22.8084% above

Trading above estimated fair value. P/e of 51x implies high growth expectations. eps growth of -33% may not justify the premium.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Neutral

4/9

Buffett

Caution

Business quality & competitive moat

Graham

Caution

Significantly above fair value

Lynch

Neutral

PEG 1.1 · Fast Grower

Greenblatt

Limited Data

Earnings yield + return on capital

Frequently Asked Questions

Is CORCEPT THERAPEUTICS INC (CORT) a good investment?
Based on AlphaStocks' composite analysis, CORCEPT THERAPEUTICS INC (CORT) scores 1.4 out of 10, earning a Avoid rating. This score is below average, suggesting caution. Trading above estimated fair value. P/e of 51x implies high growth expectations. eps growth of -33% may not justify the premium.
What is CORCEPT THERAPEUTICS INC's Piotroski F-Score?
CORCEPT THERAPEUTICS INC's Piotroski F-Score status is Neutral. The raw score is 4/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is CORT overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $23, CORT appears overvalued. The stock currently trades 84% above its estimated fair value. Trading above estimated fair value. P/e of 51x implies high growth expectations. eps growth of -33% may not justify the premium.
How does CORT compare to other Health Care stocks?
CORCEPT THERAPEUTICS INC ranks #1112 out of 1127 stocks in the Health Care sector, placing it in the top 99% of its sector by composite score. There are higher-ranked alternatives in this sector worth exploring.
What do investment models say about CORT?
AlphaStocks evaluates CORT using five proven investment models. Piotroski: Neutral; Buffett: Caution; Graham: Caution; Lynch: Neutral. These models are combined into a single composite score of 1.4/10.

Similar Stocks

PARRFTIAZN

Compare CORT with

CORT vs PARRCORT vs FTICORT vs AZN

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer